|
|
Nomes comerciais nos diversos países |
|
|
OS NOMES COMERCIAIS SÃO INDICATIVOS E OS EXCIPIENTES DA FORMULAÇÃO PODEM SER DIFERENTES CONFORME O PAÍS E FABRICANTE.
|
Acetaflur |
México |
Asoleudox |
México |
Beneflur |
Espanha, México |
Fludabin |
Peru |
Fludacel |
Índia, Peru |
Fludakebir |
Peru |
Fludalym |
Turquia |
Fludara |
Alemanha, Arábia Saudita, Austria, Bélgica, Chilli, Colômbia, Dinamarca, Egipto, Estados Unidos de América, Finlandia, França, Gran-bretanha, Hungria, Índia, Irã, Irlanda, Itália, Luxemburgo, Malásia, nova Zelândia, Países Baixos, Polonia, Portugal, Romènia, Suècia, Suicia, Venezuela |
Fludarabin |
Islandia, Itália, Noruega, Suècia, Suicia |
Fludarabina |
Argentina, Colômbia, Espanha, Peru, Romènia |
Fludarabine |
Bélgica, Canadá, Estados Unidos de América, Irã, Noruega, nova Zelândia, Suicia |
Fludarin |
Índia |
Fludarosa |
Argentina |
Forclina |
Peru |
Ludabina |
Chilli, Colômbia |
Mepredin |
Peru |
Naprobin |
Índia |
Neoflubin |
Irã |
|
|
|
|
Bibliografía : Fludarabine phosphate |
|
|
tipo |
publicação |
3 |
jornal |
Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
81 |
jornal |
Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678. |
84 |
jornal |
Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499. |
99 |
jornal |
Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
169 |
jornal |
Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363. |
182 |
jornal |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60. |
244 |
jornal |
Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913. |
249 |
jornal |
Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
307 |
jornal |
Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799. |
492 |
jornal |
Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189. |
905 |
jornal |
Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017. |
1410 |
jornal |
Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145. |
1423 |
jornal |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518. |
2344 |
Laboratório |
Stabilité physico-chimique de la gamme oncologie Ebewe Pharma France après dilution. Ebewe Pharma 2009 |
3306 |
jornal |
Trittler R. New stability studies for fludarabine according to the European Pharmacopoeia 7.0 EJOP 2012 ; 6, 1: 1-2. |
3595 |
Laboratório |
Aciclovir - Summary of Product Characteristics Hospira 2009 |
3604 |
Laboratório |
Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit Sanofi Aventis France 2012 |
3637 |
Laboratório |
Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hameln Pharmaceuticals 2014 |
3644 |
Laboratório |
Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010 |
3670 |
jornal |
Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30. |
3838 |
Laboratório |
Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007 |
4398 |
jornal |
Smith E. K., Shergold J.A., McWhinney B.C. Compatibility of intravenous busulfan with BBraun giving sets, fludarabine and Posiflush. J Pharm Pract and Res 2020 |
|
|